AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 15170905
Drug: Leflunomide in
RxNorm normalized name: Product containing leflunomide in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leflunomide in combination with infliximab
Trial: 15170905
Drug: Leflunomide in
RxNorm normalized name: Product containing leflunomide in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leflunomide in combination with adalimumab
Trial: 15170905
Drug: Lefunomide in
RxNorm normalized name: Leflunomide
DrugBank: Leflunomide (DB01097)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lefunomide in combination with etanercept
Trial: 15170905
Drug: Lefunomide in
RxNorm normalized name: Leflunomide
DrugBank: Leflunomide (DB01097)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lefunomide in combination with anakinra
Trial: 9040911
Drug: Modified obstetrics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified obstetrics curriculum at McGill University (MG)
Trial: 8176256
Drug: Terbinafine 250
RxNorm normalized name: terbinafine 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbinafine 250 mg taken each morning for 6 days before cyclosporin doses
Trial: 8176256
Drug: Cyclosporin 300
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporin 300 mg taken alone
Trial: 8176256
Drug: Terbinafine 250
RxNorm normalized name: terbinafine 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbinafine 250 mg taken on the seventh day with cyclosporin
Trial: 8176256
Drug: Terbinafine 250
RxNorm normalized name: terbinafine 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbinafine 250 mg taken with cyclosporin
Trial: 3579464
Drug: Loperamide (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loperamide (0.5 mg/kg/d)
Trial: 30445454
Drug: Brief incubation
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Brief incubation (0.3-1.2 million motile sperm/ml for 3-4 hours)
Trial: 30445454
Drug: Standard incubation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard incubation (0.3-1.2 million motile sperm/ml for 20 hours)
Trial: 25895588
Drug: Telmisartan 80
RxNorm normalized name: telmisartan 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telmisartan 80 mg + modified release nifedipine 30 mg
Trial: 25154152
Drug: 400 microg
RxNorm normalized name: Fentanyl 400 microgram buccal film
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 microg of misoprostol followed by 3 tablets of 200 microg misoprostol
Trial: 25154152
Drug: Placebo (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (3 tablets)
Trial: 19835463
Drug: Control (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (oral glucose-lowering drugs excluding thiazolidinediones)
Trial: 17093249
Drug: Neurostimulation (after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neurostimulation (after 6 months of active treatment)
Trial: 15243006
Drug: Water for
RxNorm normalized name: WATER FOR INJECTION
DrugBank: Water (DB09145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water for injection (inert control)
Trial: 12821971
Drug: 1.8 g
RxNorm normalized name: Calciquid, 1.8 g/5 mL oral syrup
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.8 g CLA per day (low dosage, LD)
Trial: 12821971
Drug: 3.6 g
RxNorm normalized name: ALCOHOL 3.6 g EXTRACORPOREAL CLOTH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.6 g CLA per day (high dosage, HD)
Trial: 1976680
Drug: Sequential use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential use of unmedicated soap (3 min) followed by 'Hibisol' (4 min)
Trial: 12028405
Drug: Lamivudine 150
RxNorm normalized name: lamivudine 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lamivudine 150 mg daily for four weeks
Trial: 9820260
Drug: Individualized Chinese
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individualized Chinese herbal formulations (n = 38)
Trial: 11768276
Drug: Standard Chinese
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard Chinese herbal formulation (n = 43)
Trial: 9820260
Drug: Both active
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both active treatment groups (individualized and standard CHM)
Trial: 29188483
Drug: Re-irradiation treatment
RxNorm normalized name: Re-Covr
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Re-irradiation treatment schedules
Trial: 26873702
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of BRAF inhibitor dabrafenib and MEK inhibitor trametinib
Trial: 26873702
Drug: Monotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy with dabrafenib (plus placebo)
Trial: 24744318
Drug: Double-fortified salt
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double-fortified salt (DFS) with 3.3 mg ferrous fumarate (1.1 mg elemental iron) per kg of iodized salt for 7.5 to 9 months
Trial: 24744318
Drug: Control iodized
RxNorm normalized name: calcium iodized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control iodized salt (47 mg/kg potassium iodate) for 7.5 to 9 months
Trial: 23677749
Drug: Cognitive rehabilitation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive rehabilitation treatment consisting of 16 one-hour individual sessions of therapist-guided cognitive training over 4 weeks, combining computer exercises and metacognitive training.
Trial: 20033244
Drug: Chewable tablet
RxNorm normalized name: Chewable Tablet
DrugBank: Bismuth subsalicylate (DB01294)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chewable tablet containing calcium and vitamin D (Calci Chew D(3), Nycomed)
Trial: 18256175
Drug: Grazax (ALK‐Abelló)
RxNorm normalized name: ALK-4290
DrugBank: ALK-4290 (DB15269)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grazax (ALK‐Abelló) for sublingual immunotherapy
Trial: 18256175
Drug: Intranasal corticosteroids
RxNorm normalized name: abiraterone and corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal corticosteroids and oral antihistamines
Trial: 16527695
Drug: Nitazoxanide tablets
RxNorm normalized name: Nitazoxanide Tablets
DrugBank: Nitazoxanide (DB00507)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nitazoxanide tablets (500 mg, twice daily for 3 days)
Trial: 16527695
Drug: Nitazoxanide oral
RxNorm normalized name: nitazoxanide Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitazoxanide oral suspension (500 mg, twice daily for 3 days)
Trial: 16527695
Drug: Placebo (matching
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (matching tablet, twice daily for 3 days)
Trial: 8755321
Drug: Oral human
RxNorm normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral human recombinant epidermal growth factor (450 mg/day)
Trial: 8755321
Drug: Oral human
RxNorm normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral human recombinant epidermal growth factor (600 mg/day)
Trial: 1407989
Drug: Levamisole alone
RxNorm normalized name: Levamisole
DrugBank: Levamisole (DB00848)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Levamisole alone (150 mg/day for 3 consecutive days)
Trial: 1407989
Drug: Levamisole in
RxNorm normalized name: doramectin / levamisole Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levamisole in combination with prednisone (150 mg/day for 3 consecutive days)
Trial: 1407989
Drug: Levamisole (alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levamisole (alone or in combination with prednisone)
Trial: 28414474
Drug: Abstinence Incentives
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Abstinence Incentives plus weekly behavioral parent training (EXP)
Trial: 26122834
Drug: pUDK-HGF (4-16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pUDK-HGF (4-16 mg)
Trial: 18230858
Drug: Fast ForWord
RxNorm normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fast ForWord Language (FFW‐L)
Trial: 18230858
Drug: All conditions
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All conditions (FFW‐L, AE, CALI, ILI)
Trial: 12949382
Drug: Tea intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tea intake (mean daily intake 525 mL)
Trial: 12949382
Drug: 4-O-methylgallic acid
RxNorm normalized name: o-Salicylsalicylic acid
DrugBank: Salsalate (DB01399)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4-O-methylgallic acid excretion (biomarker of tea-derived polyphenols)
Trial: 6441716
Drug: Oral potassium
RxNorm normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral potassium supplementation during protein-modified fast
Trial: 26607845
Drug: Erythropoiesis-stimulating agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythropoiesis-stimulating agent (ESA; darbepoetin-α) treatment
Trial: 26607845
Drug: Both ESA
RxNorm normalized name: esafoxolaner
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both ESA treatment and endurance training
Trial: 18167048
Drug: Sugar cane
RxNorm normalized name: Sugar cane pollen
DrugBank: Sugarcane (DB10906)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugar cane policosanol 20 mg daily for 8 weeks
Trial: 15320669
Drug: Caffeine (7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (7 mg.kg(‐1) of body weight)
Trial: 15320669
Drug: Placebo (vitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (vitamin C, same dosage as caffeine)
Trial: 11207403
Drug: 2-min infusion
RxNorm normalized name: Interleukin-2/diptheria toxin fusion protein
DrugBank: Denileukin diftitox (DB00004)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2-min infusion of prochlorperazine (10 mg) followed by a 15-min infusion of saline
Trial: 11207403
Drug: 15-min infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 15-min infusion of prochlorperazine (10 mg) following a 2-min infusion of saline
Trial: 9308800
Drug: Naltrexone alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone alone or naltrexone in combination with an anti-oestrogen
Trial: 8233386
Drug: Mitomycin 0.2
RxNorm normalized name: mitomycin 0.2 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mitomycin 0.2 mg
Trial: 8233386
Drug: Mitomycin 0.02
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mitomycin 0.02 mg
Trial: 3658353
Drug: Both preparations
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both preparations (2.5% in 32 microliters and 10% in 8 microliters)
Trial: 30337343
Drug: Walk by
RxNorm normalized name: By Ache
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Walk by Faith (WbF) - monthly diet and exercise education sessions
Trial: 18600190
Drug: MMRV vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MMRV vaccine (Priorix-Tetra; GlaxoSmithKline Biologicals) - 2 doses administered 42 days apart (MMRV group; N = 732)
Trial: 18600190
Drug: MMR vaccine
RxNorm normalized name: varicella-zoster virus vaccine live (Oka-Merck) strain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MMR vaccine (Priorix) coadministered with varicella vaccine (Varilrix) - 1 dose followed by a second dose of MMR vaccine 42 days later (MMR + V group; N = 238)
Trial: 6214437
Drug: Oral treatment
RxNorm normalized name: Other agents for local oral treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral treatment with tetracycline (total dose: 1st month 28.5 g; 2nd and 3rd months 15.0 g)
Trial: 30476254
Drug: Reducing calcineurin
RxNorm normalized name: Iron, reduced
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reducing calcineurin inhibitor (CNI first)
Trial: 28597604
Drug: Lesinurad 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lesinurad 400 mg daily plus febuxostat 80 mg/day
Trial: 28597604
Drug: Lesinurad 200
RxNorm normalized name: lesinurad 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lesinurad 200 mg daily plus febuxostat 80 mg/day
Trial: 28597604
Drug: Febuxostat 80
RxNorm normalized name: febuxostat 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Febuxostat 80 mg/day alone
Trial: 28597604
Drug: Lesinurad 200
RxNorm normalized name: lesinurad 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lesinurad 200 mg and 400 mg plus febuxostat
Trial: 25846114
Drug: NO3 (‐)‐rich
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NO3 (‐)‐rich beetroot juice (BR; 140 mL day(‐1); 12.8 mmol of NO3 (‐))
Trial: 25846114
Drug: NO3 (‐)‐depleted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NO3 (‐)‐depleted beetroot juice (PL; 140 mL day(‐1); 0.08 mmol NO3 (‐))
Trial: 10078674
Drug: Sufentanil (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanil (10 microg) + Transdermal Nitroglycerine (5 mg/day)
Trial: 10078674
Drug: Sufentanil (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanil (10 microg) + Transdermal Placebo
Trial: 10078674
Drug: Transdermal Nitroglycerine
RxNorm normalized name: nitroglycerin Transdermal System
DrugBank: Nitroglycerin (DB00727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal Nitroglycerine (5 mg/day) + Spinal Saline
Trial: 10078674
Drug: Spinal Saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spinal Saline + Transdermal Placebo
Trial: 24842179
Drug: BoNT‐A injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BoNT‐A injection (second dose)
Trial: 19756479
Drug: Endpoint insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Endpoint insulin dose
Trial: 19756479
Drug: End-of-study insulin
RxNorm normalized name: End-Zit
DrugBank: Octasulfur (DB09353)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: End-of-study insulin dose
Trial: 19756479
Drug: Contact frequency
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contact frequency in DPP-4 inhibitor trials
Trial: 16119485
Drug: PCEA +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCEA + CEI (continuous epidural infusion of ropivacaine 0.15% with sufentanil 0.75 microg/ml at 2 ml/h)
Trial: 12377832
Drug: Nasal CPAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal CPAP treatment for 3 weeks in patients with SDB (AHI >= 5)
Trial: 12377832
Drug: Nasal CPAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal CPAP treatment for 3 weeks in patients without SDB (AHI < 5)
Trial: 8110550
Drug: Continuous i.v.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous i.v. infusion (group A: 1.25 u. h‐1)
Trial: 8110550
Drug: Direct i.v.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct i.v. bolus administration of 10 u. every 2 h (group B: 10 u./2 h)
Trial: 3044040
Drug: iopamidol (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iopamidol (50 ml)
Trial: 3044040
Drug: iopamidol (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iopamidol (100 ml)
Trial: 3044040
Drug: diatrizoate (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: diatrizoate (50 ml)
Trial: 20688800
Drug: IPT in
RxNorm normalized name: Iptacopan
DrugBank: Iptacopan (DB16200)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IPT in combination with anti-depressant medication
Trial: 20688800
Drug: IPT in
RxNorm normalized name: Iptacopan
DrugBank: Iptacopan (DB16200)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IPT in combination with pill-placebo
Trial: 20688800
Drug: Standard antidepressant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard antidepressant therapy (medication, psychotherapy, or both)
Trial: 18765878
Drug: Sodium antimony
RxNorm normalized name: Sodium antimonyl gluconate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium antimony gluconate (SAG) at a dosage of 20 mg/kg given deep intramuscular injections for 28 days (Group A)
Trial: 18765878
Drug: Sodium antimony
RxNorm normalized name: Sodium antimonyl gluconate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium antimony gluconate (SAG) for patients whose amastigotes were resistant or withdrew due to toxicity, treated with amphotericin B (AMB) at 1 mg/kg daily for 20 days
Trial: 18765878
Drug: Total expenditure
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total expenditure on treatment
Trial: 8853536
Drug: Palliative radiotherapy
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Palliative radiotherapy (short-course fractionated treatment)
Trial: 8853536
Drug: Palliative radiotherapy
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Palliative radiotherapy (with 5HT3 antagonists)
Trial: 6653921
Drug: Domperidone, 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Domperidone, 10 mg intravenously
Trial: 27965488
Drug: Rebamipide (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rebamipide (100 mg TID for 21 days)
Trial: 27965488
Drug: Betamethasone (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betamethasone (4 mg/mL biweekly for 4 weeks)
Trial: 21756151
Drug: Q-switched alexandrite
RxNorm normalized name: Chew Q
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Q-switched alexandrite laser treatment with a 3-mm spot size
Trial: 21756151
Drug: Q-switched alexandrite
RxNorm normalized name: Chew Q
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Q-switched alexandrite laser treatment with a 4-mm spot size
Trial: 21756151
Drug: Q-switched alexandrite
RxNorm normalized name: Chew Q
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Q-switched alexandrite laser treatment with a 4-mm spot size (lower fluence)
Trial: 21756151
Drug: Q-switched alexandrite
RxNorm normalized name: Chew Q
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Q-switched alexandrite laser treatment
Trial: 20847757
Drug: DHA supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHA supplementation (20 mg/kg daily)
Trial: 9846923
Drug: EMLA cream
RxNorm normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EMLA cream 5% (1 g applied for 60-70 min)
Trial: 9846923
Drug: Placebo (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (1 g applied for 60-70 min)
Trial: 8124787
Drug: Sodium restriction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium restriction treatment
Trial: 2801550
Drug: Aspirin 325
RxNorm normalized name: aspirin 325 MG
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin 325 mg daily (Control)
Trial: 2801550
Drug: Urokinase 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urokinase 3 x 10(6) U intravenously over 30 minutes followed by heparin
Trial: 780378
Drug: 40 mg/day
RxNorm normalized name: cabozantinib s-malate 140 mg/day (80 mg x 1-20 mg x 3/day) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg/day ripazepam (CI-683)
Trial: 780378
Drug: 80 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg/day ripazepam (CI-683)
Trial: 17609906
Drug: Astragalus Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Astragalus Injection (AI) plus Stanozolol (2 mg three times a day)
Trial: 17609906
Drug: Stanozolol (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stanozolol (2 mg three times a day)
Trial: 17609906
Drug: Astragalus Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Astragalus Injection (AI) plus Stanozolol
Trial: 24782199
Drug: Ondansetron 8
RxNorm normalized name: ondansetron 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron 8 mg IV
Trial: 29318244
Drug: Freeze-dried strawberry
RxNorm normalized name: BLACKBERRY MESOCARP FREEZE DRIED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Freeze-dried strawberry (24 g d‐1, equivalent to 2 cups of fresh strawberries)
Trial: 24376273
Drug: Parenteral artesunate
RxNorm normalized name: Artesunate
DrugBank: Artesunate (DB09274)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Parenteral artesunate
Trial: 22412067
Drug: Parenteral quinine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral quinine
Trial: 15848600
Drug: ACEI/ARB therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACEI/ARB therapy (started within 14 months after surgery)
Trial: 14624284
Drug: Ondansetron (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron (4 mg bid p.o.)
Trial: 10912979
Drug: Nitrofurantoin 100
RxNorm normalized name: nitrofurantoin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrofurantoin 100 mg (two doses)
Trial: 6517812
Drug: iohexol 300
RxNorm normalized name: IOHEXOL 300MG/ML INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iohexol 300 I/ml
Trial: 2914116
Drug: ioxaglate 320
RxNorm normalized name: ioxaglate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ioxaglate 320 mg I/ml
Trial: 30025534
Drug: Full intervention
RxNorm normalized name: Full Marks
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full intervention (prescription review and league tables plus authorised feedback letter)
Trial: 30025534
Drug: Partial intervention
RxNorm normalized name: rosin partially dimerized glycerol ester
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Partial intervention (prescription review and league tables)
Trial: 30025534
Drug: Control (prescription
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (prescription review only)
Trial: 18190597
Drug: Lack of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lack of awareness of service availability (32.9%) was the most common reason for not seeking treatment.